EIPICO’s consolidated profits rise 58% YoY in H1 2024

Updated 8/14/2024 10:54:00 AM
EIPICO’s consolidated profits rise 58% YoY in H1 2024

Arab Finance: The Egyptian International Pharmaceutical Industries Company (EIPICO) reported a 58% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first half (H1) of 2024 to EGP 731.85 million from EGP 463.41 million, according to a statement.

The firm generated net sales of EGP 3.382 billion in the six-month period ended June 30th, up from EGP 2.27 billion in the same period last year.

Respecting EIPICO’s standalone results, the company achieved net profits after tax of EGP 770.386 million in H1 2024, compared to EGP 468.95 million in H1 2023.

Meanwhile, standalone net sales went up to EGP 3.26 billion from EGP 2.165 billion.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

 

 

Related News